7 May 2024Big PharmaMuireann Bolger

Teva targets Indian pharma firm over inhaler patents

Asthma is one of the most common respiratory diseases in the US and the most common chronic disease among children | Israeli pharma giant’s suit comes amid allegations that it keeps life-saving prescriptions treatments artificially high.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

Teva targets Indian pharma firm over inhaler patents

Editor's picks

Editor's picks

More features